Advertisement

Insulin-Lowering Effects of Metformin in Women with Early Breast Cancer

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Background

      Obesity has been associated with poor breast cancer outcomes. Insulin may mediate this effect, interacting with insulin receptors on breast cancer cells. Metformin, a biguanide derivative used in the treatment of diabetes, reduces insulin levels in subjects with type 2 diabetes and other insulin-resistant states. If metformin lowers insulin levels in women with breast cancer, it may also improve breast cancer outcomes.

      Patients and Methods

      We administered metformin (1500 mg per day) to 32 women with early breast cancer whose baseline insulin levels were at least 45 pmol/L to determine its effect on insulin levels.

      Results

      Twenty-two (69%) women completed the 6-month intervention. Four women (12.5%) dropped out because of gastrointestinal side effects; the others withdrew for reasons not related to toxicity. Completers were similar to noncompleters for all baseline characteristics apart from global health, overall physical condition, overall quality of life, physical function, and social function (HRQOL), which was decreased in noncompleters. Metformin significantly lowered fasting insulin levels by 15.8 pmol/L (22.4%; P = .024) and improved insulin sensitivity by 25.6% (P = .018), total cholesterol by 5.3%, and low-density lipoprotein (LDL) cholesterol by 9.1%. Metformin reduced weight by 1.9 kg (2.5%; P = .01), and it had no significant effects on HRQOL or specific gastrointestinal symptoms (appetite, nausea/vomiting, diarrhea, constipation).

      Conclusion

      Metformin significantly lowers insulin levels, and it improves insulin resistance in nondiabetic women with breast cancer. A phase III randomized trial to evaluate its effects on breast cancer outcomes is recommended.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Goodwin PJ
        Energy balance and cancer prognosis: breast cancer.
        in: McTiernan A Cancer Prevention and Management Through Exercise and Weight Control. CRC Press, Boca Raton, FL2006: 405-435
        • Goodwin PJ
        • Ennis M
        • Pritchard KI
        • et al.
        Fasting insulin and outcome in early stage breast cancer: results of a prospective cohort study.
        J Clin Oncol. 2002; 20: 42-51
        • Borugian MJ
        • Sheps SB
        • Kim-Sing C
        • et al.
        Insulin, macronutrient intake, and physical activity: Are potential indicators of insulin resistance associated with mortality from breast cancer?.
        Cancer Epidemiol Biomarkers Prev. 2004; 13: 1163-1172
        • Pollak MN
        • Chapman JW
        • Shepherd L
        • et al.
        Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA.14 adjuvant breast cancer trial.
        J Clin Oncol. 2006; 24 (Abstract 524).: 9s
        • Pasanisi P
        • Berrino F
        • De Petris M
        • et al.
        Metabolic syndrome as a prognostic factor for breast cancer recurrences.
        Int J Cancer. 2006; 119: 236-238
        • Reaven GM
        The insulin resistance syndrome: definition and dietary approaches to treatment.
        Ann Rev Nutr. 2005; 25: 391-406
        • Blackburn G
        • Waltman B
        Obesity and insulin resistance.
        in: McTiernan A Cancer Prevention and Management Through Exercise and Weight Control. CRC Press, Boca Raton, FL2006: 301-316
        • Frasca F
        • Pandini G
        • Vigneri R
        • et al.
        Insulin and hybrid/IGF receptors are major regulators of breast cancer cells.
        Breast Dis. 2003; 17: 73-89
        • Mulligan AM
        • O'Malley FP
        • Ennis M
        • et al.
        Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer.
        Breast Cancer Res Treat. 2007; 106: 39-47
        • Raptis SA
        • Dimitriadis GD
        Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers.
        Exp Clin Endocrinol Diabetes. 2001; 109: S265-S287
        • Hällsten K
        • Virtanen KA
        • Lönnqvist F
        • et al.
        Rosiglitazone but not metformin enhances insulin-and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.
        Diabetes. 2002; 51: 3479-3485
        • Virtanen KA
        • Hällsten K
        • Parkkola R
        • et al.
        Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.
        Diabetes. 2003; 52: 283-290
        • Shaw RJ
        • Lamia KA
        • Vasquez D
        • et al.
        The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin.
        Science. 2005; 310: 1642-1646
        • Marx J
        Medicine. Cancer-suppressing enzyme adds a link to type 2 diabetes.
        Science. 2005; 310: 1259
        • Evans JM
        • Donnelly LA
        • Emslie-Smith AM
        • et al.
        Metformin and reduced risk of cancer in diabetic patients.
        BMJ. 2005; 330: 1304-1305
        • Bowker SL
        • Majumdar SR
        • Veugelers P
        • et al.
        Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
        Diabetes Care. 2006; 29: 254-258
        • Jiralerspong J
        • Giordano SH
        • Meric-Bernstam F
        • et al.
        The effects of metformin on pathologic complete response (pCR) rates in diabetic breast cancer (BC) patients receiving neoadjuvant therapy (NST).
        J Clin Oncol. 2008; 26 (Abstract 528).: 13s
        • Anisimov VN
        • Berstein LM
        • Egormin PA
        Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice.
        Exp Gerontol. 2005; 40: 685-693
        • Anisimov VN
        • Egormin PA
        • Bershtein LM
        • et al.
        Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice.
        Bull Exp Biol Med. 2005; 139: 721-723
        • Wallace TM
        • Matthews DR
        The assessment of insulin resistance in man.
        Diabetes Med. 2004; 19: 527-534
        • Bonora E
        • Targher G
        • Alberiche M
        • et al.
        Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity.
        Diabetes Care. 2000; 23: 57-63
      1. Glucophage (metformin hydrochloride) [product monograph]. Sanofi-aventis Canada, Inc., Version 2.0, June 20, 2006.

        • Chlebowski RT
        • Blackburn GL
        • Thomson CA
        • et al.
        Dietary fat reduction and breast cancer outcomes: interim efficacy results from the Women's Intervention Nutrition Study.
        J Natl Cancer Inst. 2006; 98: 1767-1776
        • Pierce JP
        • Natarajan L
        • Caan BJ
        • et al.
        Influence of a diet very high in vegetables, fruits and fiber and low in fat on prognosis following treatment for breast cancer; the Women's Healthy Eating and Living (WHEL) randomized trial.
        JAMA. 2007; 298: 289-298
        • Zakikhani M
        • Dowling R
        • Fantus IG
        • et al.
        Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.
        Cancer Res. 2006; 66: 10269-10273
        • Dowling RJ
        • Zakikhani M
        • Fantus IG
        • et al.
        Metformin inhibitis mammalian target of rapamycin-dependent translation initiation in breast cancer cells.
        Cancer Res. 2007; 67: 10804-10812
        • Goodwin PJ
        Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions?.
        J Clin Oncol. 2008; 26: 833-834
        • Ligibel JA
        • Campbell N
        • Partridge A
        • et al.
        Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors.
        J Clin Oncol. 2008; 26: 907-912